U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab
Eisai's application, which was completed in early May 2022, has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of January 6, 2023.
For Early Alzheimer's Disease Under the Accelerated Approval Pathway
TOKYO, July 6, 2022 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. Eisai's application, which was completed in early May 2022, has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of January 6, 2023.
"Alzheimer's disease is a serious disease that causes significant disability and burden to the people living with Alzheimer's disease and their families. Treatment options for Alzheimer's disease are limited and creation of new treatment options is strongly encouraged. Eisai employees have spent time with people living with Alzheimer's disease to truly understand their feelings and challenges and have been working to create new treatments for many years," said Haruo Naito, Chief Executive Officer at Eisai. "The acceptance of lecanemab's BLA with priority review is an important milestone in serving people living with Alzheimer's disease who have been waiting for new treatment options to address an underlying pathology of Alzheimer's disease. We will continue to actively cooperate with the FDA's review in an effort to bring this new treatment option to people living with Alzheimer's disease and their families as soon as possible."
"We believe in a future where people living with Alzheimer's disease will have different treatment options to address this complex disease, and today's BLA acceptance with priority review by FDA is an important step towards this vision," said Michel Vounatsos, Chief Executive Officer at Biogen. "Together with Eisai, we are committed to continuing our work to address the tremendous unmet need for these patients and their families."
The Clarity AD Phase 3 clinical study for lecanemab in early AD is ongoing and Eisai completed enrollment in March 2021 with 1,795 patients. The readout of the primary endpoint data of Clarity AD will occur in the Fall of 2022. The FDA has agreed that the results of Clarity AD, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. Eisai utilized the FDA's Accelerated Approval Pathway in an effort to streamline the submission process for the potential traditional approval of lecanemab in order to expedite patients' access to lecanemab. Dependent upon the results of the Clarity AD clinical trial, Eisai will submit for traditional approval of lecanemab to the FDA during Eisai's fiscal year 2022, which ends on March 31, 2023.
In Japan, in March 2022, Eisai initiated the submission of application data to the Pharmaceuticals and Medical Devices Agency (PMDA) under the prior assessment consultation system with the aim of obtaining early approval for lecanemab. Eisai aims to file for the manufacturing and marketing approval based on the results of Clarity AD during Eisai's fiscal year 2022. Also, in Europe, based on the results of the Clarity AD study, Eisai plans to submit a new drug application in fiscal year 2022.
Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
For more information, visit www.eisai.com/news/2022/pdf/enews202254pdf.pdf.
Source: Eisai
Copyright 2022 JCN Newswire . All rights reserved.